VistaGen Therapeutics
is a stem cell company which centers its attention on drug rescue and
regenerative medicine – a type of tissue engineering and molecular biology that
deals with the process of replacing, engineering or regenerating human cells,
to restore or establish normal function. Believing better cells lead to better
medicine, the company feels a vital aspect to making these cells is controlling
the differentiation of human pluripotent stem cells commonly referred to as,
‘the building blocks’ of all cells within the human body. VSTA’s stem cell
R&D teams have focused on controlling the differentiation of pluripotent
stem cells for over 15 years to produce multiple types of mature, functional,
adult human cells, with emphasis on human heart and liver cells for drug rescue
applications.
The company believes
a notable number of pharmaceutical companies are experiencing critical R&D
productivity issues as evidenced be their low number of FDA-approved products
each year. As an example, the U.S. pharmaceutical industry invested over $51
billion in R&D and the Center for Drug Evaluation and Research (CDER) of
the FDA approved a total of only thirty-nine (39) novel drugs, known as New
Molecular Entities (NMEs). In 2013, CDER approved only twenty-seven (27) NMEs,
thirteen (13) of which NME approvals (48%) were received by only five (5)
pharmaceutical companies, including Bayer (2), GlaxoSmithKline (4), Johnson
& Johnson (3), Roche (2) and Takeda (2).
Despite significant
R&D investment levels by the global pharmaceutical industry since 2003, the
FDA has only approved an average of twenty-six (26) NME’s annually. The
company’s position is that many pharmaceutical companies with established
products that are no longer patent protected are also experiencing substantial
market pressure from generic competition. As a result of weak R&D
productivity, shrinking product pipelines and generic competition, VSTA
believes there will continue to be a critical need among pharmaceutical
companies to license the new, safer Drug Rescue Variants they are focused on
developing.
Pointing to
estimates that show about one-third of all potential new drugs candidates fail
in their development stages due to unexpected safety concerns, VSTA presents
its drug rescue programs as a viable solution which can recapture substantial
value from the prior investment by pharmaceutical companies whose research has
been paused on the once promising drug candidate due to heart or liver safety
concerns.
For more information
on the company, visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment